Aditxt (NASDAQ: ADTX), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, has released a shareholder update outlining its three innovation programs and strategic M&A initiatives. The update notes that subsidiary Pearsanta submitted a bid to acquire substantially all assets of Lucira Health Inc., including Lucira Connect and FDA-approved at-home combination COVID-19 and flu tests. The company was chosen as a backup bidder. Despite an objection filed by Aditxt noting issues related to fairness and good faith, Pearsanta remains the backup bidder. Earlier this month, Aditxt formed a wholly owned subsidiary, Adivir Inc., focused on the company’s therapeutics and antimicrobial program. The company continues to consider a potential transaction with Cellvera, a company focused on discovering, developing and commercializing antimicrobial therapies across a broad spectrum of infectious diseases. Aditxt continues to move forward with its human clinical trials in Germany, studying Adimune. The studies will focus on psoriasis, with the objective being to add human trials in the United States later this year. “Aditxt’s vision is dedicated to a new era of precision medicine through individual immune monitoring and modulation,” said Aditxt cofounder, chair and CEO Amro Albanna in the press release. “We are laser-focused on advancing each of our innovation programs toward commercialization. Adimune’s initiation of ADI-100 manufacturing is measurable progress of Adimune toward our 2023 strategic goals.”
To view the full press release, visit https://ibn.fm/50mNa
About Aditxt Inc.
Aditxt is a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system. The company’s mission of “Making Promising Innovations Possible, Together” is defined by its growing ecosystem of research institutions, global industry partners and shareholders that inform and inspire. Aditxt’s diverse innovation portfolio includes Adimune Inc.(TM), developing and designing a new class of therapeutics for retraining the immune system to address organ rejection, autoimmunity, and allergies; Adivir Inc.(TM), focused on identifying, developing and commercializing new ways to treat infectious diseases; and Pearsanta Inc.(TM), which offers personalized immune monitoring for a wide range of health conditions, including hereditary cancer, wounds and cardiomyopathy. For more information, please visit www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork